We evaluated NB73, a newly developed small-drug inhibitor of FOXM1 (Fig. 5a) [10], to facilitate the bench-to-bedside translation of FOXM1-targeted myeloma therapy. Here, FOXM1 is linked to plasma cell myeloma.